Mylan's $465M settlement shortchanges taxpayers: study

Fierce Pharma ------ When the U.S. government agreed on a $465 million Medicaid misclassification settlement with Mylan, did it agree on an amount that was too low? A new study says that’s likely the case. By calculating publicly available data on acquisition costs for Mylan’s EpiPen and incorporating prescription volumes plus branded and generic rebate rates under the federal healthcare program, Harvard researchers conclude that the settlement seems a little light. At a bare minimum, Mylan avoided paying $426.1 million in rebates due to EpiPen's misclassification as a noninnovator med, according to the study, published in JAMA Internal Medicine. Their calculations, however, reach back only to 2012, and Mylan picked up EpiPen in 2007, the group points out. To learn more click on the picture below to read the article.